Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Single and Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Effects of ARO-ANG3 in Adult Healthy Volunteers and in Dyslipidemic Patients

NCT03747224 is registered in ClinicalTrials.gov with Arrowhead Pharmaceuticals as lead sponsor.

NCT NCT03747224
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03747224 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Single and Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Effects of ARO-ANG3 in Adult Healthy Volunteers and in Dyslipidemic Patients
Lead sponsor
Arrowhead Pharmaceuticals
Phase
Phase 1
Overall status
Completed
Start date
January 7, 2019
Completion date
May 17, 2021
Enrollment
93 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

dyslipidemias, familial hypercholesterolemia, hypertriglyceridemia